2 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Mats Heyman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy - Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Mats Heyman | 6430 | 2020-07-13 | 2026-08-12 |
| A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Observational - Leukemia, Acute Lymphoblastic | Recruiting | Mats Heyman | 500 | 2019-08-29 | 2026-08-13 |
Leukemia (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
Imatinib Mesylate (1) · Watchful Waiting (1) · blinatumomab (1)
Denmark (2) · Estonia (2) · Finland (2) · Iceland (2) · Lithuania (2) · Norway (2) · Spain (2) · Sweden (2) · Belgium (1) · France (1) · Germany (1) · Ireland (1) · Netherlands (1) · Portugal (1) · United Kingdom (1)